Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 1/2009

01-01-2009 | Research Paper

The tumor microenvironment and metastatic disease

Authors: Sarah Jane Lunt, Naz Chaudary, Richard P. Hill

Published in: Clinical & Experimental Metastasis | Issue 1/2009

Login to get access

Abstract

The microenvironment of solid tumors is a heterogeneous, complex milieu for tumor growth and survival that includes features such as acidic pH, low nutrient levels, elevated interstitial fluid pressure (IFP) and chronic and fluctuating levels of oxygenation that relate to the abnormal vascular network that exists in tumors. The metastatic potential of tumor cells is believed to be regulated by interactions between the tumor cells and their extracellular environment (extracellular matrix (ECM)). These interactions can be modified by the accumulation of genetic changes and by the transient alterations in gene expression induced by the local tumor microenvironment. Clinical and experimental evidence suggests that altered gene expression in response to the hypoxic microenvironment is a contributing factor to increased metastatic efficiency. A number of genes that have been implicated in the metastatic process, involving angiogenesis, intra/extravasation, survival and growth, have been found to be hypoxia-responsive. The various metastatic determinants, genetic and epigenetic, somatic and inherited may serve as precedents for the future identification of more genes that are involved in metastasis. Much research has focused on genetic and molecular properties of the tumor cells themselves. In the present review we discuss the epigenetic and physiological regulation of metastasis and emphasize the need for further studies on the interactions between the pathophysiologic tumor microenvironment and the tumor extracellular matrix.
Literature
1.
2.
3.
4.
5.
6.
7.
8.
Nordsmark M, Eriksen JG, Gebski V et al (2007) Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 83(3):389–397. doi:10.​1016/​j.​radonc.​2007.​04.​021 PubMed
9.
Hockel M, Schlenger K, Aral B et al (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56(19):4509–4515PubMed
10.
Fyles A, Milosevic M, Hedley D et al (2002) Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20(3):680–687. doi:10.​1200/​JCO.​20.​3.​680 PubMed
11.
Brizel DM, Scully SP, Harrelson JM et al (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56(5):941–943PubMed
12.
Cairns RA, Kalliomaki T, Hill RP (2001) Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 61(24):8903–8908PubMed
13.
14.
Graeber TG, Osmanian C, Jacks T et al (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379(6560):88–91. doi:10.​1038/​379088a0 PubMed
15.
16.
Krishnamachary B, Berg-Dixon S, Kelly B et al (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63(5):1138–1143PubMed
17.
Brizel DM, Schroeder T, Scher RL et al (2001) Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 51(2):349–353. doi:10.​1016/​S0360-3016(01)01630-3 PubMed
18.
Weidner N (1998) Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 184(2):119–122. doi:10.1002/(SICI)1096-9896(199802)184:2<119::AID-PATH17>3.0.CO;2-D
19.
Sundfor K, Lyng H, Rofstad EK (1998) Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 78(6):822–827PubMed
20.
West CM, Cooper RA, Loncaster JA et al (2001) Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res 61(7):2907–2910PubMed
21.
22.
Stackpole CW, Groszek L, Kalbag SS (1994) Benign-to-malignant B16 melanoma progression induced in two stages in vitro by exposure to hypoxia. J Natl Cancer Inst 86(5):361–367. doi:10.​1093/​jnci/​86.​5.​361 PubMed
23.
Rofstad EK, Danielsen T (1999) Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer 80(11):1697–1707. doi:10.​1038/​sj.​bjc.​6690586 PubMed
24.
25.
Woodhouse EC, Chuaqui RF, Liotta LA (1997) General mechanisms of metastasis. Cancer 80(8 Suppl):1529–1537. doi:10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F
26.
27.
Baluk P, Morikawa S, Haskell A et al (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163(5):1801–1815PubMed
28.
Kallinowski F, Tyler G, Mueller-Klieser W et al (1989) Growth-related changes of oxygen consumption rates of tumor cells grown in vitro and in vivo. J Cell Physiol 138(1):183–191. doi:10.​1002/​jcp.​1041380124 PubMed
29.
Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449–6465PubMed
30.
Thomlinson RH, Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9(4):539–549PubMed
31.
32.
Durand RE, Raleigh JA (1998) Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res 58(16):3547–3550PubMed
33.
Brown JM (1979) Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism for reoxygenation. Br J Radiol 52:650–656PubMed
34.
Sutherland RM, Franko AJ (1980) On the nature of the radiobiologically hypoxic fraction in tumors. Int J Radiat Oncol Biol Phys 6(1):117–120PubMed
35.
36.
Lanzen J, Braun RD, Klitzman B et al (2006) Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res 66(4):2219–2223. doi:10.​1158/​0008-5472.​CAN-03-2958 PubMed
37.
38.
39.
Subarsky P, Hill RP (2008) Graded hypoxia modulates the invasive potential of HT1080 fibrosarcoma and MDA MB231 carcinoma cells. Clin Exp Metastasis 25(3):253–264PubMed
40.
41.
42.
43.
Dvorak HF, Nagy JA, Feng D et al (1999) Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237:97–132PubMed
44.
45.
Semenza GL (2007) Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007; (407): cm8
46.
47.
48.
49.
Mabjeesh NJ, Amir S (2007) Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 22(5):559–572PubMed
50.
Semenza GL, Nejfelt MK, Chi SM et al (1991) Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA 88(13):5680–5684. doi:10.​1073/​pnas.​88.​13.​5680 PubMed
51.
Bardos JI, Ashcroft M (2005) Negative and positive regulation of HIF-1: a complex network. Biochim Biophys Acta 1755(2):107–120PubMed
52.
53.
54.
Brahimi-Horn C, Pouyssegur J (2006) The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 93(8):E73–E80PubMed
55.
56.
Maxwell PH, Dachs GU, Gleadle JM et al (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94(15):8104–8109. doi:10.​1073/​pnas.​94.​15.​8104 PubMed
57.
Aragones J, Schneider M, Van Geyte K et al (2008) Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 40(2):170–180. doi:10.​1038/​ng.​2007.​62 PubMed
58.
59.
60.
61.
Liu YL, Yu JM, Song XR et al (2006) Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines. Cancer Biol Ther 5(10):1320–1326PubMed
62.
63.
Winter SC, Shah KA, Han C et al (2006) The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 107(4):757–766. doi:10.​1002/​cncr.​21983 PubMed
64.
Maynard MA, Qi H, Chung J et al (2003) Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 278(13):11032–11040. doi:10.​1074/​jbc.​M208681200 PubMed
65.
Gu YZ, Moran SM, Hogenesch JB et al (1998) Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7(3):205–213PubMed
66.
Makino Y, Cao R, Svensson K et al (2001) Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414(6863):550–554. doi:10.​1038/​35107085 PubMed
67.
Berra E, Benizri E, Ginouves A et al (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22(16):4082–4090. doi:10.​1093/​emboj/​cdg392 PubMed
68.
Appelhoff RJ, Tian YM, Raval RR et al (2004) Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279(37):38458–38465. doi:10.​1074/​jbc.​M406026200 PubMed
69.
70.
D’Angelo G, Duplan E, Boyer N et al (2003) Hypoxia up-regulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses during reoxygenation. J Biol Chem 278(40):38183–38187. doi:10.​1074/​jbc.​M302244200 PubMed
71.
Erez N, Milyavsky M, Eilam R et al (2003) Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Res 63(24):8777–8783PubMed
72.
Moeller BJ, Cao Y, Vujaskovic Z et al (2003) Reactive oxygen species and hypoxia inducible factor-1alpha serve as important vascular stabilizing elements in tumors following radiotherapy. Int J Radiat Oncol Biol Phys 57(2 Suppl):S320–S321. doi:10.​1016/​S0360-3016(03)01198-2
73.
Semenza GL, Prabhakar NR (2007) HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid Redox Signal 9(9):1391–1396. doi:10.​1089/​ars.​2007.​1691 PubMed
74.
75.
Bonitsis N, Batistatou A, Karantima S et al (2006) The role of cadherin/catenin complex in malignant melanoma. Exp Oncol 28(3):187–193PubMed
76.
77.
78.
Imai T, Horiuchi A, Wang C et al (2003) Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163(4):1437–1447PubMed
79.
80.
Tanimoto K, Yoshiga K, Eguchi H, et al (2003) Hypoxia-inducible factor-1{alpha} polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24(11):1779–1783
81.
82.
83.
84.
85.
86.
Festuccia C, Dolo V, Guerra F et al (1998) Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16(6):513–528. doi:10.​1023/​A:​1006590217724 PubMed
87.
Graham CH, Forsdike J, Fitzgerald CJ et al (1999) Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 80(4):617–623. doi:10.1002/(SICI) 1097-0215(19990209) 80:4<617::AID-IJC22>3.0.CO;2-C
88.
Osinsky SP, Ganusevich II, Bubnovskaya LN et al (2005) Hypoxia level and matrix metalloproteinases-2 and -9 activity in Lewis lung carcinoma: correlation with metastasis. Exp Oncol 27(3):202–205PubMed
89.
Rofstad EK, Rasmussen H, Galappathi K et al (2002) Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res 62(6):1847–1853PubMed
90.
Canning MT, Postovit LM, Clarke SH et al (2001) Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Exp Cell Res 267(1):88–94. doi:10.​1006/​excr.​2001.​5243 PubMed
91.
92.
93.
Corso S, Migliore C, Ghiso E et al (2008) Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 27(5):684–693PubMed
94.
Ratajczak MZ, Zuba-Surma E, Kucia M et al (2006) The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20(11):1915–1924. doi:10.​1038/​sj.​leu.​2404357 PubMed
95.
Ben-Baruch A (2008) Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 25(4):345–356PubMed
96.
Nagasawa T (2000) A chemokine, SDF-1/PBSF, and its receptor, CXC chemokine receptor 4, as mediators of hematopoiesis. Int J Hematol 72(4):408–411PubMed
97.
98.
99.
Engl T, Relja B, Marian D et al (2006) CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia (New York, N.Y.) 8(4):290–301. 10.​1593/​neo.​05694
100.
101.
Wykoff CC, Pugh CW, Harris AL et al (2001) The HIF pathway: implications for patterns of gene expression in cancer. Novartis Found Symp 240:212–225 discussion 25–31PubMedCrossRef
102.
103.
104.
105.
Abedi H, Zachary I (1997) Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 272(24):15442–15451. doi:10.​1074/​jbc.​272.​24.​15442 PubMed
106.
Isaacs JS, Jung YJ, Mimnaugh EG et al (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277(33):29936–29944. doi:10.​1074/​jbc.​M204733200 PubMed
107.
Rousseau S, Houle F, Kotanides H et al (2000) Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 275(14):10661–10672. doi:10.​1074/​jbc.​275.​14.​10661 PubMed
108.
109.
Zhu Y, Denhardt DT, Cao H et al (2005) Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24(43):6555–6563PubMed
110.
111.
Tuck AB, Arsenault DM, O’Malley FP et al (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18(29):4237–4246. doi:10.​1038/​sj.​onc.​1202799 PubMed
112.
Tuck AB, O’Malley FP, Singhal H et al (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121(6):578–584PubMed
113.
Tuck AB, O’Malley FP, Singhal H et al (1998) Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79(5):502–508. doi:10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3
114.
Thalmann GN, Sikes RA, Devoll RE et al (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5(8):2271–2277PubMed
115.
Agrawal D, Chen T, Irby R et al (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94(7):513–521PubMed
116.
117.
Le QT, Sutphin PD, Raychaudhuri S et al (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9(1):59–67PubMed
118.
Overgaard J, Eriksen JG, Nordsmark M et al (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6(10):757–764. doi:10.​1016/​S1470-2045(05)70292-8 PubMed
119.
Bramwell VH, Tuck AB, Wilson SM et al (2005) Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biol Ther 4(12):1336–1341PubMedCrossRef
120.
121.
Shweiki D, Itin A, Soffer D et al (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398):843–845. doi:10.​1038/​359843a0 PubMed
122.
Forsythe JA, Jiang BH, Iyer NV et al (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16(9):4604–4613PubMed
123.
124.
Veikkola T, Karkkainen M, Claesson-Welsh L et al (2000) Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60(2):203–212PubMed
125.
Rofstad EK, Danielsen T (1998) Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma. Br J Cancer 77(6):897–902PubMed
126.
Solorzano CC, Baker CH, Bruns CJ et al (2001) Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 16(5):359–370. doi:10.​1089/​1084978017533542​67 PubMed
127.
Kanayama H, Yano S, Kim SJ et al (1999) Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice. Clin Exp Metastasis 17(10):831–840. doi:10.​1023/​A:​1006792007063 PubMed
128.
Jang A, Hill RP (1997) An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. Clin Exp Metastasis 15(5):469–483. doi:10.​1023/​A:​1018470709523 PubMed
129.
130.
131.
Desbaillets I, Diserens AC, Tribolet N et al (1997) Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 186(8):1201–1212. doi:10.​1084/​jem.​186.​8.​1201 PubMed
132.
Yoshida A, Yoshida S, Khalil AK et al (1998) Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 39(7):1097–1106PubMed
133.
134.
Harris AL, Zhang H, Moghaddam A et al (1996) Breast cancer angiogenesis––new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Res Treat 38(1):97–108. doi:10.​1007/​BF01803788 PubMed
135.
136.
Rofstad EK, Halsor EF (2000) Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 60(17):4932–4938PubMed
137.
138.
Raghunand N, Gatenby RA, Gillies RJ (2003) Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 76(Suppl 1):S11–S22PubMed
139.
140.
141.
142.
143.
Schlappack OK, Zimmermann A, Hill RP (1991) Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells. Br J Cancer 64(4):663–670PubMed
144.
145.
Moellering RE, Black KC, Krishnamurty C et al (2008) Acid treatment of melanoma cells selects for invasive phenotypes. Clin Exp Metastasis 25(4):411–425PubMed
146.
Kalliomaki T, Hill RP (2004) Effects of tumour acidification with glucose + MIBG on the spontaneous metastatic potential of two murine cell lines. Br J Cancer 90(9):1842–1849PubMed
147.
Walenta S, Snyder S, Haroon ZA et al (2001) Tissue gradients of energy metabolites mirror oxygen tension gradients in a rat mammary carcinoma model. Int J Radiat Oncol Biol Phys 51(3):840–848. doi:10.​1016/​S0360-3016(01)01700-X PubMed
148.
Fukumura D, Xu L, Chen Y et al (2001) Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 61(16):6020–6024PubMed
149.
Less JR, Posner MC, Boucher Y et al (1992) Interstitial hypertension in human breast and colorectal tumors. Cancer Res 52:6371–6374PubMed
150.
Nathanson SD, Nelson L (1994) Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma. Ann Surg Oncol 1:333–338PubMed
151.
Curti BD, Urba WJ, Alvord WG et al (1993) Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res 53:2204–2207PubMed
152.
Boucher Y, Kirkwood JM, Opacic D (1991) Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 51:6691–6694PubMed
153.
Gutmann R, Leunig M, Feyh J et al (1992) Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res 52:1993–1995PubMed
154.
Milosevic M, Fyles A, Hedley D et al (2001) Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 61(17):6400–6405PubMed
155.
Roh HD, Kalnicki S, Buchsbaum R et al (1991) Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res 51:6695–6698PubMed
156.
157.
Leu AJ, Berk DA, Lymboussaki A et al (2000) Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 60:4324–4327PubMed
158.
Lunt SJ, Kalliomaki TM, Brown A et al (2008) Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours. BMC Cancer 8(1):2. doi:10.​1186/​1471-2407-8-2 PubMed
159.
Jain RK, Tong RT, Munn LL (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67(6):2729–2735. doi:10.​1158/​0008-5472.​CAN-06-4102 PubMed
160.
Heldin CH, Rubin K, Pietras K et al (2004) High interstitial fluid pressure––an obstacle in cancer therapy. Nat Rev Cancer 4(10):806–813. doi:10.​1038/​nrc1456 PubMed
161.
Oldberg A, Kalamajski S, Salnikov AV et al (2007) Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma. Proc Natl Acad Sci USA 104(35):13966–13971. doi:10.​1073/​pnas.​0702014104 PubMed
162.
163.
164.
Pietras K, Rubin K, Sjoblom T et al (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62(19):5476–5484PubMed
165.
Pietras K, Ostman A, Sjoquist M et al (2001) Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61(7):2929–2934PubMed
166.
Mocanu JD, Yip KW, Alajez NM et al (2007) Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy. Mol Ther 15(5):921–929PubMed
167.
168.
Lee CG, Heijn M, di Tomaso E et al (2000) Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60(19):5565–5570PubMed
169.
Curnis F, Sacchi A, Corti A (2002) Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 110(4):475–482PubMed
170.
Pietras K, Stumm M, Hubert M et al (2003) STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 9(10 pt 1):3779–3787PubMed
171.
Rofstad EK, Tunheim SH, Mathiesen B et al (2002) Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res 62(3):661–664PubMed
172.
Salnikov AV, Heldin NE, Stuhr LB et al (2006) Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int J Cancer 119(12):2795–2802. doi:10.​1002/​ijc.​22217 PubMed
173.
174.
Tufto I, Lyng H, Rofstad EK (1996) Interstitial fluid pressure, perfusion rate and oxygen tension in human melanoma xenografts. Br J Cancer 74(Suppl 27):S252–S255
175.
176.
177.
Boucher Y, Baxter LT, Jain RK (1990) Interstitial pressure gradients in tissue isolated and subcutaneous tissues: implications for therapy. Cancer Res 50:4478–4484PubMed
178.
179.
180.
Clarke MF, Dick JE, Dirks PB et al (2006) Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66(19):9339–9344PubMed
181.
182.
183.
Giatromanolaki A, Koukourakis MI, Sivridis E et al (2001) Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85(6):881–890. doi:10.​1054/​bjoc.​2001.​2018 PubMed
184.
Schoppmann SF, Fenzl A, Schindl M et al (2006) Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat 99(2):135–141. doi:10.​1007/​s10549-006-9190-3 PubMed
185.
Okada K, Osaki M, Araki K et al (2005) Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. Anticancer Res 25(4):3003–3009PubMed
186.
187.
188.
Giatromanolaki A, Koukourakis MI, Stathopoulos GP et al (2000) Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer. Oncol Res 12(1):33–41PubMed
189.
190.
Marjon PL, Bobrovnikova-Marjon EV, Abcouwer SF (2004) Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress. Mol Cancer 3(1):4. doi:10.​1186/​1476-4598-3-4 PubMed
191.
Bobrovnikova-Marjon EV, Marjon PL, Barbash O et al (2004) Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-kappaB and activating protein-1. Cancer Res 64(14):4858–4869. doi:10.​1158/​0008-5472.​CAN-04-0682 PubMed
192.
Rofstad EK, Mathiesen B, Henriksen K et al (2005) The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res 65(6):2387–2396. doi:10.​1158/​0008-5472.​CAN-04-3039 PubMed
193.
194.
Griffiths L, Dachs GU, Bicknell R et al (1997) The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 57(4):570–572PubMed
195.
Maity A, Solomon D (2000) Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia. Exp Cell Res 255(2):250–257. doi:10.​1006/​excr.​1999.​4804 PubMed
196.
Memarzadeh S, Kozak KR, Chang L et al (2002) Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer. Proc Natl Acad Sci USA 99(16):10647–10652. doi:10.​1073/​pnas.​152127499 PubMed
197.
Yoon SY, Lee YJ, Seo JH et al (2006) uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line. Cell Res 16(1):75–81. doi:10.​1038/​sj.​cr.​7310010 PubMed
198.
199.
Lukacova S, Khalil AA, Overgaard J et al (2005) Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum. Int J Radiat Biol 81(12):937–944. doi:10.​1080/​0955300060056761​6 PubMed
200.
201.
202.
Shim H, Lau SK, Devi S et al (2006) Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun 346(1):252–258. doi:10.​1016/​j.​bbrc.​2006.​05.​110 PubMed
203.
Staller P, Sulitkova J, Lisztwan J et al (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425(6955):307–311. doi:10.​1038/​nature01874 PubMed
204.
205.
206.
Ide T, Kitajima Y, Miyoshi A et al (2006) Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer 119(12):2750–2759. doi:10.​1002/​ijc.​22178 PubMed
207.
208.
Postovit LM, Abbott DE, Payne SL et al (2008) Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration. J Cell Biochem 103(5):1369–1378PubMed
209.
Zhang L, Hill RP (2004) Hypoxia enhances metastatic efficiency by up regulating mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res 64(12):4180–4189
210.
211.
212.
213.
Yoon DY, Buchler P, Saarikoski ST et al (2001) Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem Biophys Res Commun 288(4):882–886. doi:10.​1006/​bbrc.​2001.​5867 PubMed
214.
Niizeki H, Kobayashi M, Horiuchi I et al (2002) Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells. Br J Cancer 86(12):1914–1919. doi:10.​1038/​sj.​bjc.​6600331 PubMed
215.
Metadata
Title
The tumor microenvironment and metastatic disease
Authors
Sarah Jane Lunt
Naz Chaudary
Richard P. Hill
Publication date
01-01-2009
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 1/2009
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-008-9182-2

Other articles of this Issue 1/2009

Clinical & Experimental Metastasis 1/2009 Go to the issue

Research Paper

Introduction to special issue on ‘epigenetic and physiological regulation of metastasis’

Review

Three-dimensional context regulation of metastasis

Review

Epigenetic contributions to cancer metastasis

Research Paper

Influence of diet on metastasis and tumor dormancy

Research Paper

Tumor dormancy due to failure of angiogenesis: role of the microenvironment

Review

Societal interactions in ovarian cancer metastasis: a quorum-sensing hypothesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits